GeoVax, Inc. has started its HIV/AIDS human clinical trials in different sites around the United States. The culmination of this study is in lieu of the recently received "Safe to Proceed" status for a new Investigational New Drug (IND) from the USFDA.
The human clinical trials include testing of both DNA and MVA components of an HIV/AIDS vaccine developed by a team of researchers at GeoVax, the Yerkes National Primate Research Center at Emory University and the Emory Vaccine Center, as well as colleagues at the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC).
Participating sites in the United States are: University of Alabama at Birmingham, Saint Louis University, University of Maryland and Vanderbilt University.
Read more at GeoVax News (a pdf file).
.jpg)
Comment Preview